793 related articles for article (PubMed ID: 30672018)
1. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
2. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
[TBL] [Abstract][Full Text] [Related]
3. Fully human antibody V
Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
[TBL] [Abstract][Full Text] [Related]
4. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
[TBL] [Abstract][Full Text] [Related]
5. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
6. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
8. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
9. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N
Front Immunol; 2024; 15():1389018. PubMed ID: 38720898
[TBL] [Abstract][Full Text] [Related]
10. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
[TBL] [Abstract][Full Text] [Related]
11. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
12. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
13. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells.
Zare H; Rajabibazl M; Rasooli I; Ebrahimizadeh W; Bakherad H; Ardakani LS; Gargari SL
Int J Biol Markers; 2014 Jun; 29(2):e169-79. PubMed ID: 24425321
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
15. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
[TBL] [Abstract][Full Text] [Related]
16. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
[TBL] [Abstract][Full Text] [Related]
17. The application of prostate specific membrane antigen in CART‑cell therapy for treatment of prostate carcinoma (Review).
Ullah K; Addai Peprah F; Yu F; Shi H
Oncol Rep; 2018 Dec; 40(6):3136-3143. PubMed ID: 30542701
[TBL] [Abstract][Full Text] [Related]
18. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
19. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.
Mo F; Duan S; Jiang X; Yang X; Hou X; Shi W; Carlos CJJ; Liu A; Yin S; Wang W; Yao H; Yu Z; Tang Z; Xie S; Ding Z; Zhao X; Hammock BD; Lu X
Signal Transduct Target Ther; 2021 Feb; 6(1):80. PubMed ID: 33627635
[TBL] [Abstract][Full Text] [Related]
20. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
